WO2014085727A1 - System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysilogical properties - Google Patents
System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysilogical properties Download PDFInfo
- Publication number
- WO2014085727A1 WO2014085727A1 PCT/US2013/072439 US2013072439W WO2014085727A1 WO 2014085727 A1 WO2014085727 A1 WO 2014085727A1 US 2013072439 W US2013072439 W US 2013072439W WO 2014085727 A1 WO2014085727 A1 WO 2014085727A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- impedance
- electrode
- pair
- electrodes
- cells
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 183
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 137
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000010009 beating Methods 0.000 title abstract description 49
- 230000035899 viability Effects 0.000 title abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 531
- 238000005259 measurement Methods 0.000 claims abstract description 32
- 230000004044 response Effects 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims description 101
- 238000002847 impedance measurement Methods 0.000 claims description 87
- 239000000758 substrate Substances 0.000 claims description 87
- 230000008859 change Effects 0.000 claims description 55
- 230000000638 stimulation Effects 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 28
- 230000005284 excitation Effects 0.000 claims description 20
- 230000008602 contraction Effects 0.000 claims description 19
- 230000008878 coupling Effects 0.000 claims description 18
- 238000010168 coupling process Methods 0.000 claims description 18
- 238000005859 coupling reaction Methods 0.000 claims description 18
- 238000004891 communication Methods 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 238000003491 array Methods 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 25
- 238000013459 approach Methods 0.000 description 20
- 108090000862 Ion Channels Proteins 0.000 description 16
- 102000004310 Ion Channels Human genes 0.000 description 16
- 108091006146 Channels Proteins 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 206010048610 Cardiotoxicity Diseases 0.000 description 14
- 231100000259 cardiotoxicity Toxicity 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000010304 firing Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 230000002269 spontaneous effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 108700019146 Transgenes Proteins 0.000 description 10
- 230000001451 cardiotoxic effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 231100000457 cardiotoxic Toxicity 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000036982 action potential Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 230000021164 cell adhesion Effects 0.000 description 7
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960001404 quinidine Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- -1 urine Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 4
- 229960002370 sotalol Drugs 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 3
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000000801 calcium channel stimulating agent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229960004427 isradipine Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 2
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000009067 heart development Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000037877 cardiac atrophy Diseases 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009539 inhibitory neurotransmission Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000003368 label free method Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 239000005355 lead glass Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
- G01N33/4836—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures using multielectrode arrays
Definitions
- This invention relates to the field of cell-based assays and more specifically to devices, systems and methods for electro-stimulation of excitable cells, such as cardiomyocyte or cardiomyocyte precursor cells and performing extracellular recording and/or impedance monitoring of electro-stimulated cells.
- Bioelectronics is a progressing interdisciplinary research field that involves the integration of biomaterials with electronic devices. Bioelectronics methods have been used for analyzing cells and assaying biological molecules and cells. In one type of application, cells are cultured on microelectrodes and cell-electrode impedance or cell- substrate impedance is measured and analyzed to monitor cellular changes, such as changes in cell morphology.
- PCT Application No. PCT/US03/22557 titled “Impedance Based Devices and Methods for Use in Assays", discloses a device for detecting cells and/or molecules on an electrode surface.
- the device detects cells and/or molecules through measurement of impedance changes resulting from the attachment or binding of cells and/or molecules to the electrode surfaces.
- a number of embodiments of the device are disclosed, together with the apparatuses, and systems for using such devices to perform certain cell based assays.
- Cardiotoxicity itself can entail a number of short-term and long term cellular events including directly affecting the beating rate of cardiomyocytes, viability of cardiomyocytes and morphology of cardiomyocytes as would occur in hypertrophy.
- the core of the current issue in pharmacological safety assessment and drug development is the lack of a reliable screening methodology capable of monitoring potential drug-mediated cardiotoxicity and distinguishing between different modes of cardiotoxicity. What is urgently needed in the field is a good cell-based model system as well as a monitoring system with a physiological and functional readout that can provide incisive information regarding potential cardiotoxic side effects of drugs.
- the drug discovery industry has undertaken two different approaches for toxicological assessment of drug candidate leads in cardiac function.
- the first approach involves isolation of cardiomyocytes directly from a mammalian species such as rats and dogs followed by electrophysiological and viability studies on the isolated cardiomyocytes. This approach is extremely labor-intensive, time consuming and costly and at the same time not very amenable to the high throughput demands of pharmaceutical industry
- ES cells embryonic stem cells
- Mammalian ES cells are self-renewing cells derived from the inner cell mass of a blastocyst stage embryo, which can be differentiated into multiple different cell types. It has been demonstrated that the mouse ES cells as well as human ES cells can be differentiated into cardiomyocytes, which retain the ability to beat in culture.
- ES cells The differentiation of ES cells first involves an intermediate in vitro developmental stage in which ES cells form compact cell structures known as embryoid bodies. These embryoid bodies can induce the developmental program of ES cell differentiation into multiple cell types including cardiomyocytes, which are distinguished in culture by their ability to undergo spontaneous beating. These ES derived in vitro differentiated cardiomyocytes recapitulates the normal development of cardiomyocytes as evidenced by the stage-specific expression of cardiomyocyte specific genes. All the known transcription factors, ion channels and structural proteins that are part of normal heart development and function in vivo are also expressed in ES-derived cardiomyocyte.
- ES cells are self-renewing, cells in culture can serve as an excellent source for continuous production of cardiomyocytes. Therefore, these cardiomyocytes which behave in every way like normal cardiomyocytes isolated from the heart tissue itself addresses the ever important supply problem and for the first time allows for assessment of cardiac function and its modulation by lead candidate drugs and compounds in relatively large scale in both viability assays, assessment of morphology and in monitoring the beating function of cardiomyocytes. Furthermore, because the technology exists to selectively knockout or express trans-genes in ES cells, it provides an excellent model system to study the role of certain genes in cardiac development and function without having to be concerned about adverse affects on overall embryonic development in transgenic animals.
- transgenes in ES cells have been utilized as a way to enrich for preparation of cardiomyocytes that are 100% pure.
- the gene encoding GFP has been cloned downstream of a cardiac-specific promoter and then introduced into ES cells.
- Embryoid cells, which ultimately differentiate into cardiomyocytes, will therefore express the GFP transgenes and these cells can be easily isolated by cell sorting techniques and therefore an enriched cardiomyocyte population can be obtained.
- the present invention discloses devices, systems and methods for performing impedance monitoring and/or extracellular recording of excitable cells, such as cardiomyocytes in cell based assays that encourage the continued and regular beating of excitable cells such that the cardiotoxicity of potential drugs can be assessed.
- the devices, systems and methods provide improved characterization of excitable cells in response to compound administration to assess responses of cardiomyocytes including cardiotoxic effects, while increasing efficiency of throughput for potential drug candidates.
- the invention further provides improved characterization of cells during differentiation processes related to development of cardiomyocytes.
- a system for monitoring excitable cells which includes a device having at least one well, each well having a bottom having a nonconductive substrate, wherein the substrate has a surface suitable for attachment of excitable cells; a power source configured to deliver an electrical signal capable of electro-stimulating excitable cells; and at least one analyzing module for measuring an electrical property from electro-stimulated excitable cells, characterized in that each well includes a pair of electro-stimulation electrodes configured to receive the electrical signal from the power source thereby delivering an electro-stimulating signal to the well for electro-stimulation of excitable cells attached to the substrate; and at least a second pair of electrodes communicatively coupled to the at least one analyzing module, which is selected from the group consisting of a pair of impedance monitoring electrodes communicatively coupled to the at least one analyzing module in the form of an impedance analyzer thereby permitting impedance monitoring of excitable cells attached to the substrate, and an extracellular recording electrode pair communicative
- the electrical signal is a series of pulses at a regular time interval, such as but not limited to 0.5 seconds to 2 seconds.
- the electrical signal can vary but is preferably IV to 2.5V for 0.5-2 milliseconds.
- a percentage of a surface area of the bottom of the at least one well occupied by the pair of electro-stimulation electrodes can vary but in some embodiments is selected from the group consisting of 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, and 70% or more.
- the electro-stimulation electrodes independently includes an unbranched electrode structure or a branched electrode structure.
- the at least second pair of electrodes is the pair of impedance monitoring electrodes and the analyzing module is in the form of the impedance analyzer.
- the pair of impedance monitoring electrodes can be provided in a variety of configurations but is preferably a pair of interdigitated electrode structures, wherein each electrode structure comprises a plurality of electrode elements.
- the pair of impedance monitoring electrodes can be a pair of electrode structures having a same surface area.
- the impedance analyzer monitors impedance at millisecond time resolution
- the extracellular recording electrode pair as a third pair of electrodes.
- at least one electrode of the pair of electro-stimulation electrodes is also at least one electrode of the extracellular recording electrode pair thereby permitting electro-stimulation of excitable cells and extracellular recording of attached cells using a same electrode at different time points.
- the at least second pair of electrodes can be the extracellular recording electrode pair and the analyzing module can be the extracellular recording amplifier.
- the extracellular recording electrode pair includes a recording electrode and a reference electrode.
- the recording electrode has a diameter from about 10 ⁇ to about 200 ⁇ or from about 30 ⁇ to about 100 ⁇ .
- the extracellular recording electrode pair comprises a recording electrode and a reference electrode, further wherein a ratio of the area of reference electrode to the area of recording electrode is selected from the group consisting of 2 or more, 10 or more, 100 or more, 1,000 or more, and 10,000 or more.
- a second recording electrode is provided having a same diameter as a first.
- At least one electrode of the pair of electro-stimulation electrodes is also at least one electrode of a pair of impedance monitoring electrodes thereby permitting electro-stimulation of excitable cells and impedance monitoring of attached cells using a same electrode at different time points and thus electro-stimulation together with simultaneous impedance monitoring using as few as four total electrodes.
- the pair of impedance monitoring electrodes is a pair of interdigitated electrode structures, wherein each electrode structure comprises a plurality of electrode elements.
- at least one electrode of the pair of impedance monitoring electrodes is the reference electrode.
- a device for monitoring excitable cells including at least one well, each well having a bottom having a nonconductive substrate, wherein the substrate has a surface suitable for attachment of excitable cells; a pair of electro-stimulation electrodes positioned on the substrate within the at least one well and configured to electro-stimulate the excitable cells; and at least a second pair of electrodes positioned within the at least one well and selected from the group consisting of a pair of impedance monitoring electrodes and extracellular recording electrode pair, wherein the pair of impedance monitoring electrodes is configured for monitoring cell-substrate impedance of cells attached to the substrate, and wherein the extracellular recording electrode pair is configured for monitoring extracellular potential of cells attached to the substrate.
- a percentage of a surface area of the bottom of the at least one well occupied by the pair of electro-stimulation electrodes can vary but may be selected from the group consisting of 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, and 70% or more.
- each of the electro-stimulation electrodes independently include an unbranched electrode structure or a branched electrode structure.
- the at least second pair of electrodes is the pair of impedance measurement electrodes.
- each electrode within the pair of impedance measurement electrodes can inlcude a plurality of electrode elements and can be configured as one half of a pair of interdigated electrodes.
- electrode of the pair of impedance monitoring electrodes has a same surface area.
- the at least second pair of electrodes can be the extracellular recording electrode pair.
- the extracellular recording electrode pair includes a recording electrode and reference electrode; however, two or more recording electrodes may be associated with one or more reference electrodes.
- each recording electrode has a diameter from about 10 ⁇ to about 200 ⁇ or from about 30 ⁇ to about 100 ⁇ ⁇ .
- the ratio of the area of reference electrode to the area of recording electrode can vary but may be selected from the group consisting of 2 or more, 10 or more, 100 or more, 1,000 or more, and 10,000 or more.
- the reference electrode of the recording and reference electrode pair can have a branched or an unbranched structure.
- At least one electrode is shared between the pair of electrostimulation electrodes and the at least second electrode pair.
- the at least second electrode pair is the pair of impedance measurement electrodes.
- the at least second electrode pair is the extracellular recording electrode pair.
- the at least second electrode pair is the pair of impedance measurement electrodes, and device further includes the extracellular recording pair as a third pair of electrodes.
- at least one electrode can be shared between the pair of impedance measurement electrodes and the recording and reference electrode pair.
- a method for monitoring excitable cells includes providing a system for electro-stimulating excitable cells and monitor impedance and/or extracellular potential of stimulated cells which has at least two pairs of electrodes; adding a sample of excitable cells to the device; electro- stimulating the excitable cells with electro-stimulation electrodes; and monitoring electro-stimulated cells through the at least second pair of electrodes.
- the excitable cells are cardiomyocytes or cardiomyocyte precursor cells. Electro-stimulation can be performed at a plurality of time intervals, optionally at regular time intervals.
- a pair of impedance monitoring electrodes can communicatively coupled to an impedance analyzer, thereby permitting the step of monitoring electro-simulated cells to include monitoring impedance of electro-stimulated cells.
- impedance is monitored in millisecond time resolution.
- the methods may also include adding a compound suspected of affecting excitation contraction coupling of the excitable cells to the at least one well for analysis.
- the methods may include calculating and comparing an impedance-based parameter prior to and after adding the compound to identify whether a change occurs in the excitable cells in response to the compound.
- the impedance-based parameter is compared between at least two different electro-stimulation intervals.
- suitable impedance-based parameter examples include an impedance measurement, a cell index calculated from the impedance measurement, and a cell change index calculated from the cell index.
- the impedance based parameter is plotted as an impedance-based curve over time and the step of comparing the impedance-based parameter between at least two different electro-stimulation intervals includes comparing impedance-based curves between at least to different electro-stimulation intervals.
- the excitable cells are added to each of at least two wells and the step of performing impedance measurements is performed for each of the at least two wells, the method can therefore further include adding a compound suspected of affecting excitation contraction coupling of the excitable cells to a first of the at least two wells to form a test well and adding a control to a second of the lease two wells to form a control well, and comparing an impedance-based parameter between the test well and control well.
- suitable impedance-based parameters can be the impedance measurement, a cell index calculated from the impedance measurement, and a cell change index calculated from the cell index.
- the impedance-based parameter is plotted as an impedance-based curve over time and the step of comparing the impedance-based parameter between the test well and control well includes comparing the impedance-based curve of the test well to the impedance based curve of the control well.
- the extracellular recording electrode pair is communicatively coupled to the an extracellular recording amplifier, and the step of monitoring electro-simulated cells includes extracellular recording of electro-stimulated cells.
- the embodiments include plotting extracellular potential from the extracellular recording of electro-stimulated cells over time to form a field potential curve. Extracellular recording can be performed before and after the step of electro- stimulating the excitable cells.
- the method includes adding a compound suspected of affecting excitation contraction coupling of the excitable cells to the at least one well for extracellular recording.
- extracellular potential of the excitable cells prior to and after adding the compound can be compared to identify changes in extracellular potential in response to the compound.
- Extracellular potential may be plotted over time to form a field potential curve for analysis.
- excitable cells are added to each of at least two wells and the step of performing extracellular recording measurements is performed for each of the at least two wells.
- the method can include adding a compound suspected of affecting excitation contraction coupling of the excitable cells to a first of the at least two wells to form a test well and adding a control to a second of the lease two wells to form a control well, and comparing extracellular potential between the test well and control well. Extracellular recording can be performed before and after adding the compound.
- a pair of impedance monitoring electrodes are communicatively coupled to the impedance analyzer and the extracellular recording electrode pair is communicatively coupled to the extracellular recording amplifier, and the step of monitoring electro-stimulated cells includes impedance monitoring and extracellular recording of electro-stimulated cells.
- at least one electrode is shared between two pairs of electrodes selected from the group consisting of the pair of electro-stimulation electrodes and the pair of impedance monitoring electrodes, the pair of electro-stimulation electrodes and the extracellular recording electrode pair, and the pair of impedance monitoring electrodes and the extracellular recording electrode pair. In such configurations, the sharing of the electrode(s) is performed by switching communication to the at least one electrode.
- the method include adding a compound suspected of affecting excitation contraction coupling of the excitable cells to the at least one well.
- Such methods may also include comparing an impedance-based parameter and extracellular field potential prior to and after adding the compound to identify whether a change occurs in the excitable cells in response to the compound.
- the impedance-based parameter is selected from the group consisting of an impedance measurement, a cell index calculated from the impedance measurement, and a cell change index calculated from the cell index.
- the impedance based parameter is plotted as an impedance-based curve over time and the extracellular field potential is plotted as field potential over time and the step of comparing the impedance- based parameter and extracellular field potential between at least two different electrostimulation intervals includes comparing impedance-based curves and comparing field potential curves between at least two different electro-stimulation intervals.
- FIG. 1 is a schematic illustration showing a correlation of a cell index impedance parameter and field potential for a contracton-relaxation interval in a primary neonatal rat cardiomyocyte.
- FIGS. 2A-D depict different configurations of electrode arrays 10A-D that can perform electro-stimulation, impedance measurement and extracellular recording.
- FIG. 3 depicts an exemplary system of a device 100, a combined analyzer 200 having switchable electro-stimulation, impedance monitoring, and extracellular recording functions and computer 300.
- FIGS. 4A-D depict examples of the graphical interface for software used in data acquisition (FIGS 4A-C) and data analysis (FIG. 4D).
- FIG. 5 shows an exemplary cardio experimental work flow chart.
- FIGS. 6A-B show results from extracellular recording of field potential and impedance monitoring of HL-1 cells (FIG. 6 A) and Cor AT cells (FIG. 6B).
- FIGS 7A-C show results from extracellular recording of field potential and impedance monitoring of CorAT cells with the addition of Solatol at 0 ⁇ (FIG. 7A), 200 ⁇ (FIG. 7B) or 400 ⁇ (FIG. 7C).
- FIGS. 8A-F show results from extracellular recording of field potential and impedance monitoring of rat primary cardiomyocyte cells with the addition of Quinidine at 0 ⁇ (FIG. 8A), 2 ⁇ (FIG. 8B), 4 ⁇ (FIG. 8C), 8 ⁇ (FIG. 8D) or 16 ⁇ (FIG. 8E).
- FIG. 8F shows an overlay of an interval of ECR field potentials from each of FIGS. 8A-E.
- FIG. 8G shows an overlay of an interval of impedance from each of FIGS. 8A-E.
- FIG. 9 shows changes in impedance and extracellular recording of field potential of Cor.AT cells during electrostimulation and without electrostimulation.
- FIG. 10 shows changes in impedance and extracellular recording of field potential of reat primary cardiomyocyte during electrostimulation and without electrostimulation.
- FIGS. 11A-F shows a series of curves from an experiment where HL-1 cells
- FIG. 11 A were electro-stimulated to induce measurable changes in field potential (FP) (FIG. 11B), which could then be modulated through the addition of different concentrations of the calcium channel blocker Israpidine (FIGS. 11C-E).
- FIG. 11F being an overlay of field potential curves from FIGS. 11A-E.
- FIGS. 12A-G show a series of curves from an experiment where HL-1 cells (FIG. 12A) where electrostimulated to induce measureable changes in field potential (FP)(FIG. 12B).
- a calcium channel activator was added to culture and modulation of the field potential (FP) was detected (FIG. 12C).
- the culture was paced use electro- stimulation (FIG. 12D).
- Addition of different concentrations of antagonist (FIGS. 12E- F) were added and modulated the field potential (FP).
- FIG. 12G is an overlay of FIGS. 12A-F)
- FIGS. 13A-C show a series of curves from an experiment documenting the electro-stimulation of CorAT cells and the pacing of cardiomyocytes
- FIG. 13 A overlays impedance (via cell index) and field potential in response to electro-stimulation and after electro-stimulation stops.
- impedance and field potential are split in that the upper panel is impedance and the lower panel is field potential.
- FIG. 13C is an enlarged view showing a single interval and the relationship between impedance and field potential.
- FIGS. 14A-B show the electro-stimulation of rat primary cardiomyocytes and the impedance and field potential profiles in response to the regular pacing of cardiomyocytes.
- FIGS. 15A-B show results from experiments monitoring the field potential of neurons after treatment with bicuculline (FIG. 15 A) or Glutamate (FIG. 15B).
- the devices systems and methods permit high resolution monitoring of the beating cycle of a population of cardiomyocyte cells thus can detect changes in cell beating, such as shifts in contraction or relaxation that would be difficult to detect otherwise.
- FIG. 1 an exemplary plot of the relationship between impedance and extracellular recording is shown in FIG. 1, where high resolution monitoring demonstrates that contraction and relaxation of cells, such as cardiomyocytes can be effectively monitored using an impedance-based approach and more preferably together with extracellular recording.
- a peak in impedance is followed by a peak in field potential. According changes in either impedance or extracellular recording provides insight as to changes occurring in the excitable cell population.
- impedance monitoring and extracellular recording can be used as a high throughput approach to screen for potential cardiotoxic affects of compounds. Further it also provides approaches for monitoring embryonic stem cell development into cardiomyocytes and implications associated with genetic knock outs and transgene expression at different developmental stages.
- biocompatible membrane or biocompatible surface means a membrane or surface that does not have deleterious effects on cells, including the viability, attachment, spreading, motility, growth, cell division or cell beating.
- biomolecular coating refers a coating on a surface that comprises a molecule that is a naturally occurring biological molecule or biochemical, or a biochemical derived from or based on one or more naturally occurring biomolecules or biochemicals.
- a biological molecule coating can include an extracellular matrix component (e.g., fibronectin, collagens), or a derivative thereof, or can comprise a biochemical such as polylysine or polyornithine, which are polymeric molecules based on the naturally occurring biochemicals lysine and ornithine.
- Polymeric molecules based on naturally occurring biochemicals such as amino acids can use isomers or enantiomers of the naturally-occuring biochemicals.
- organic compound coating or a “coating having an organic compound) as used herein refers to a coating on a substrate that includes an organic compound.
- an organic compound may include a natural ligand or an agonist or an antagonist for a cell surface receptor.
- Electrode is a structure having a high electrical conductivity, that is, an electrical conductivity much higher than the electrical conductivity of the surrounding materials, which in the present invention are typically nonconductive.
- An “extracellular recording electrode” or “recording electrode” or “ECR electrode” is such a structure used to detect electrical signal corresponding to extracellular field potential of the cell or cell population. For instance, a “recording electrode” may be used to monitor the extracellular field potential of a cardiomyocyte during the generation of membrane action potentials.
- a “reference electrode” is the complementary structure used to complete the electrical circuit during extracellular recording.
- an “impedance electrode”, “impedance monitoring electrode” , “impedance measurement electrode” or “impedance electrode structure” is a structure, such as an electrode, used for impedance monitoring.
- An “impedance electrode” may also operate as an extracellular recording electrode or electro-stimulation and thus may provide both impedance monitoring and extracellular recording measurements or both impedance monitoring and electro-stimulation, albeit at different time points.
- an “electrode structure” refers to a single electrode, particularly one with a complex structure (as, for example, a spiral electrode structure), or a collection of at least two electrode elements that are electrically connected together. All the electrode elements within an “electrode structure” are electrically connected.
- electrode element refers to a single structural feature of an electrode structure, such as, for example, a fingerlike or branched projection of an interdigitated electrode structure.
- An electrode structure may have a plurality of electrode elements.
- a "unitary electrode structure” refers to a single electrode that is unbranched. That is, a "unitary electrode structure” does not include a plurality of electrode elements.
- an unitary electrode structure may be of a circle, a square or other geometry.
- a "pair of electrodes" or “electrode pair” is two or more electrode structures that are constructed to have dimensions and spacing such that they can, when connected to a signal source, operate as a unit to generate an electrical field in the region of spaces around the electrode structures.
- Preferred electrode structure units of the present invention can measure impedance changes due to cell attachment to an electrode surface.
- Non-limiting examples of electrode structure units are interdigitated electrode structure units and concentric electrode structure units.
- electrode bus is a portion of an electrode that connects individual electrode elements or substructures.
- An electrode bus provides a common conduction path from individual electrode elements or individual electrode substructures to another electrical connection.
- an electrode bus can contact each electrode element of an electrode structure and provide an electrical connection path to electrical traces that lead to a connection pad.
- electrode traces or “electrically conductive traces” or “electrical traces”, are electrically conductive paths that extend from electrodes or electrode elements or electrode structures toward one end or boundary of a device or apparatus for connecting the electrodes or electrode elements or electrode structures to a electrostimulation power source, an analyzer or amplifier, such as an impedance analyzer or amplifier, a voltage amplifier and the like. Electrical communication of electrostimulation electrodes, impedance electrodes or extracellular recording electrodes typically involves connection to a connection pad using an "electrode trace.”
- connection pad is an area on an apparatus or a device of the present invention which is electrically connected to at least one electrode or all electrode elements within at least one electrode structure on an apparatus or a device and which can be operatively connected to external electrical circuits (e.g., an impedance measurement circuit or a signal source or an extracellular voltage signal amplifier).
- external electrical circuits e.g., an impedance measurement circuit or a signal source or an extracellular voltage signal amplifier.
- the electrical connection between a connection pad and an impedance measurement circuit, an extracellular recording circuit or a signal source can be direct or indirect, through any appropriate electrical conduction means such as leads or wires.
- Such electrical conduction means may also go through electrode or electrical conduction paths located on other regions of the apparatus or device.
- Interdigitated means having projections coming one direction that interlace with projections coming from a different direction in the manner of the fingers of folded hands (with the caveat that interdigitated electrode elements preferably do not contact one another).
- At least two electrodes fabricated on the substrate means that the at least two electrodes are fabricated or made or produced on the substrate.
- the at least two electrodes can be on the same side of the substrate or on the different side of the substrate.
- the substrate may have multiple layers, the at least two electrodes can be either on the same or on the different layers of the substrate.
- At least two electrodes fabricated to a same plane of the substrate means that, if the nonconducting substrate has multiple layers, the at least two electrodes are fabricated to the same layer of the substrate.
- an electrode positioned on a different plane refers to the positioning of an electrode, typically an external electrode or reference electrode, above, below or along a different surface angle than that which it is compared.
- An “electrode positioned on a different plane” may be parallel to that of the first.
- the . . . electrodes (or electrode structures) have substantially the same surface area means that the surface areas of the electrodes referred to are not substantially different from each other, so that the impedance change due to cell attachment or growth on any one of the electrodes (or electrode structures) referred to will contribute to the overall detectable change in impedance to a same or similar degree as the impedance change due to cell attachment or growth on any other of the electrodes (or electrode structures) referred to. In other words, where electrodes (or electrode structures) have substantially the same surface area, any one of the electrodes can contribute to overall change in impedance upon cell attachment or growth on the electrode.
- the ratio of surface area between the largest electrode and the smallest electrode that have “substantially the same surface area” is less than 10.
- the ratio of surface area between the largest electrode and the smallest electrode of an electrode array is less than 5, 4, 3, 2, 1.5, 1.2 or 1.1. More preferably, the at least two electrodes of an electrode structure have nearly identical or identical surface area.
- the device has a surface suitable for cell attachment or growth
- the electrode and/or non-electrode area of the apparatus has appropriate physical, chemical or biological properties such that cells of interest can viably attach on the surface and new cells can continue to attach, while the cell culture grows, on the surface of the apparatus.
- the device, or the surface thereof contain substances necessary for cell viability or growth. These necessary substances, e.g., nutrients or growth factors, can be supplied in a medium.
- a suspension of viable cardiomyocytes, neuron cells, muscle cells or other excitable cells or other adherent cells such as epithelial cells or endothelial cells is added to the "surface suitable for cell attachment" when at least 50% of the cells are adhering to the surface within twelve hours.
- a surface that is suitable for cell attachment has surface properties so that at least 70% of the cells are adhering to the surface within twelve hours of plating (i.e., adding cells to the chamber or well that comprises the said device).
- the surface properties of a surface that is suitable for cell attachment results in at least 90% of the cells adhering to the surface within twelve hours of plating.
- the surface properties of a surface that is suitable for cell attachment results in at least 90% of the cells adhering to the surface within eight, six, four, two hours of plating.
- detectable change in impedance between or among said electrodes means that the impedance between or among the electrodes (or electrode structures) would have a significant change that can be detected by an impedance analyzer or impedance measurement circuit when cells attach on the electrode surfaces.
- the impedance change refers to the difference in impedance values when cells are attached to the electrode surface and when cells are not attached to the electrode surface, or when the number, type, activity, adhesiveness, or morphology of cells attached to the electrode-comprising surface of the apparatus changes. In most cases, the change in impedance is larger than 0.1% to be detectable.
- the detectable change in impedance is larger than 1%, 2%, 5%, or 8%. More preferably, the detectable change in impedance is larger than 10%.
- Impedance between or among electrodes is typically a function of the frequency of the applied electric field for measurement. "Detectable change in impedance between or among the electrodes” does not require the impedance change at all frequencies being detectable. "Detectable change in impedance between or among said electrodes” only requires a detectable change in impedance at any single frequency (or multiple frequencies).
- impedance has two components, resistance and reactance (reactance can be divided into two categories, capacitive reactance and inductive reactance).
- impedance is the electrical or electronic impedance.
- the method for the measurement of such impedance is achieved by, (1) applying a voltage between or among the electrodes at a given frequency (or multiple frequencies, or having specific voltage waveform) and monitoring the electrical current through said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage amplitude value by the current amplitude value to derive the impedance value; (2) applying an electric current of a single frequency component (or multiple frequencies or having specific current wave form) through said electrodes and monitoring the voltage resulted between or among said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage amplitude value by the current amplitude value to derive the impedance value; (3) other methods that can measure or determine electric impedance.
- each well contains substantially same number . . . of cells” means that the lowest number of cells in a well is at least 50% of the highest number of cells in a well. Preferably, the lowest number of cells in a well is at least 60%, 70%, 80%), 90%), 95% or 99% of the highest number of cells in a well. More preferably, each well contains an identical number of cells.
- each well contains . . .same type of cells means that, for the intended purpose, each well contains same type of cells; it is not necessary that each well contains exactly identical type of cells.
- each well contains same type of mammalian cells, e.g., human cells, or different mammalian cells, e.g., human cells as well as other non-human mammalian cells such as mice, goat or monkey cells, etc.
- each well contains . . . serially different concentration of a test compound
- each well contains a test compound with a serially diluted concentrations, e.g., an one-tenth serially diluted concentrations of 1 M, 0.1 M, 0.01 M, etc.
- dose-response curve means the dependent relationship of response of cells on the dose concentration of a test compound.
- the response of cells can be measured by many different parameters. For example, a test compound is suspected to have cytotoxicity and cause cell death. Then the response of cells can be measured by percentage of non-viable (or viable) cells after the cells are treated by the test compound. Plotting this percentage of non- viable (or viable) cells as a function of the dose concentration of the test compound constructs a dose response curve. In the present application, the percentage of non-viable (or viable) cells can be expressed in terms of measured impedance values, or in terms of cell index derived from impedance measurement, or in terms of cell change indexes.
- cell index can be shown to have a linear correlation or positive correlation with the number of viable cells in a well from which cell index was derived from the impedance measurement.
- dose-response curve the dose-response curve
- cell index not only correlate with the number of viable cells in the wells but also relate to the cell morphology and cell attachment.
- plotting cell index versus dose concentration provides information not only about number of cells but also about their physiological status (e.g. cell morphology and cell adhesion).
- an important advantage offered by the system and devices of the present invention is that in a single experiment, one can obtain "dose-response curves" at multiple time points since the system allows for the continuous monitoring of cells and provides impedance measurement at many time points over a time range as short as a few minutes to as long as days or weeks.
- sample refers to anything which may contain a moiety to be isolated, manipulated, measured, quantified, detected or analyzed using apparatuses, microplates or methods in the present application.
- the sample may be a biological sample, such as a biological fluid or a biological tissue.
- biological fluids include suspension of cells in a medium such as cell culture medium, urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like.
- Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s).
- the biological samples may further include cell suspensions, solutions containing biological molecules (e.g. proteins, enzymes, nucleic acids, carbohydrates, chemical molecules binding to biological molecules).
- a “liquid (fluid) sample” refers to a sample that naturally exists as a liquid or fluid, e.g., a biological fluid.
- a “liquid sample” also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material.
- a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue.
- a “compound” or “test compound” is any compound whose activity or direct or indirect effect or effects on cells is investigated in any assay.
- a test compound can be any compound, including, but not limited to, a small molecule, a large molecule, a molecular complex, an organic molecule, an inorganic molecule, a biomolecule or biological molecule such as but not limited to a lipid, a steroid, a carbohydrate, a fatty acid, an amino acid, a peptide, a protein, a nucleic acid, or any combination thereof.
- a test compound can be a synthetic compound, a naturally occurring compound, a derivative of a naturally-occurring compound, etc. The structure of a test compound can be known or unknown.
- a compound is capable of, or is suspected of, effecting cell adhesion or cell spreading.
- a compound is capable of, or is suspected of, stimulating or inhibiting cell adhesion or cell spreading.
- a compound is capable of, or is suspected of, interacting with an ion channel.
- a compound is capable of, or is suspected of, modulating cardiomyocyte excitation contraction coupling or beating.
- a compound is capable of, or is suspected of, interacting with cells (for example, binding to cell surface receptor, or inhibiting certain intracellular signal transduction pathway, or activating cells).
- a "known compound” is a compound for which at least one activity is known.
- a known compound preferably is a compound for which one or more direct or indirect effects on cells is known.
- the structure of a known compound is known, but this need not be the case.
- the mechanism of action of a known compound on cells is known, for example, the effect or effects of a known compound on cells can be, as nonlimiting examples, effects on cell beating, cell viability, cell adhesion, apoptosis, cell differentiation, cell proliferation, cell morphology, cell cycle, IgE-mediated cell activation or stimulation, receptor-ligand binding, cell number, cell quality, cell cycling, cell adhesion, cell spreading, etc.
- Cell Index is a parameter that can derived from measured impedance values and that can be used to reflect the change in impedance values.
- a "Normalized Cell Index" at a given time point is calculated by dividing the Cell
- the Normalized Cell Index is 1 at the reference time point.
- the reference time point is the last time point for impedance measurement before the treatment of the cells.
- a "delta cell index" at a given time point is calculated by subtracting the cell index at a standard time point from the cell index at the given time point.
- the delta cell index is the absolute change in the cell index from an initial time (the standard time point) to the measurement time.
- a "Cell Change Index” or "CO” is a parameter derived from Cell Index and
- CO at a time point is equal to the 1 st order derive of the Cell Index with respect to time, divided by the Cell Index at the time point. In other words, CO is calculated as
- extracellular recording refers to measuring, monitoring and/or recording of electric potential difference between two electrodes typically caused by ionic movement or ionic current through the media or solution due to charge fluctuations across ion channels in a cell or in a group of cells.
- the cells are in the media or the solution.
- the extracellular recording electrodes are located outside of the cells.
- an exemplary device includes at least one well, each well having a bottom having a nonconductive substrate, the substrate having a surface suitable for attachment of excitable cells; a pair of electro-stimulation electrodes positioned on the substrate within the at least one well and configured to electro-stimulate the excitable cells; and at least a second pair of electrodes positioned within the at least one well.
- the at least second pair of electrodes can be a pair of impedance monitoring electrodes or an extracellular recording electrode pair.
- the second pair of electrodes is the pair of impedance monitoring electrodes and the extracellular recording pair is provided as a third electrode pair.
- the pair of impedance monitoring electrodes are configured to measure cell-substrate impedance of cells attached to the substrate, and the extracellular recording electrode pair are configured to measure extracellular potential of cells attached to the substrate. Accordingly, the device permits the electro-stimulation of excitable cells, such as cardiomyocytes while various embodiments permit impedance monitoring, extracellular recording or both impedance monitoring and extracellular recording of excitable cells.
- the substrate has a surface suitable for attachment of excitable cells
- the attachment of excitable cells on the substrate provides a suitable form for measuring extracellular potential through the extracellular recording electrode pair, and measuring cell-substrate impedance through the pair of impedance monitoring electrodes, and still further that the attached excitable cells can be electro-stimulated or paced by electro-stimulation when appropriate electrical signals are delivered to the pair of electro-stimulation electrodes.
- the cell culture can maintain a regular beating interval to test the cardiotoxic affects of various compounds or monitor the development of cardiomyocyte precursor cells to cardiomyocytes.
- the device includes one or more fluid-impermeable receptacles which serve as fluid containers or wells.
- Such receptacles may be reversibly or irreversibly attached to or formed within the substrate or portions thereof (such as, for example, wells formed as in a microtiter plate).
- Suitable fluid container materials comprise plastic, glass, or plastic coated materials such as a ceramic, glass, metal, etc. Descriptions and disclosure of devices that comprise fluid containers can be found in U.S. Patent No. 7,470,533, herein incorporated by reference for all disclosure of fluid containers and fluid container structures that can engage a substrate comprising electrodes for impedance measurements, including their dimensions, design, composition, and methods of manufacture.
- commercial tissue culture plates can be adapted to fit the substrate. Bottomless plates may also be custom-made to preferred dimensions.
- the device may have any number of wells as desired for the particular experiment. For instance, the device may have 1 well, 2 wells, 3 wells, 6 wells, 8 wells, 12 wells, 24 wells, 36 wells, 96 wells, 384 wells, 1536 wells or the like.
- well diameters are from about 1 millimeter to about 20 millimeters, more preferably from about 2 millimeters to about 8 millimeters at the bottom of the well (the end disposed on the substrate).
- the wells can have a uniform diameter or can taper toward the bottom so that the diameter of the container at the end in contact with the substrate is smaller than the diameter of the opposing end.
- the surface of the substrate is suitable for cell attachment and optionally growth.
- the nonconducting substrate is planar, and is flat or approximately flat.
- the substrate may be constructed from a variety of nonconductive materials known in the present art, including, but not limited to, silicon dioxide on silicon, silicon-on-insulator (SOI) wafer, glass (e.g., quartz glass, lead glass or borosilicate glass), sapphire, ceramics, polymer, fiber glass, plastics, e.g., polyimide (e.g. Kapton, polyimide film supplied by DuPont), polystyrene, polycarbonate, polyvinyl chloride, polyester, polypropylene and urea resin.
- SOI silicon-on-insulator
- the substrate is biocompatible with excitable cells such as cardiomyocytes; however, materials that are not biocompatible can be made biocompatible by applying a biocompatible or biomolecular coating with a suitable material, such as a biocompatible polymer or the like.
- a suitable material such as a biocompatible polymer or the like.
- attachment or growth along the substrate or electrodes may be enhanced by pre-coating the substrate with a protein or compound that facilitates attachment or growth.
- a protein or compound that facilitates attachment or growth Such compounds may be chosen according to techniques known in the cellular biology arts; however, in some embodiments fibronectin is effective.
- the substrate may be chemically modified to display reactive groups or binding moieties such as adhesion molecules that enhance cell attachment, particularly ES cells that are cardiomyocyte precursor cells or cardiomyocytes.
- electrodes of the invention may be applied to the substrate followed by joining the electrode applied substrate to a plate of bottomless wells or may be applied to a well already having the substrate as a bottom. Electrodes may be formed from larger sheets of conductive metal, such as via laser ablation of a metallic film and may be applied directly to the substrate. Alternatively, electrodes may be printed on the substrate using printing techniques such as those similar to ink-jet printing where a conductive fluid having ultraviolet (UV) curable monomers, polymers or compounds is printed on the substrate, then a light source is applied to cure the applied conductive fluid to form electrodes.
- UV ultraviolet
- conductive material may be applied directly to a planar substrate or may be inserted into grooves laser ablated or formed into the substrate surface.
- a glue such as a UV curable glue, can be applied between the substrate and electrode or above the electrode for added security. Further, when applying conductive fluids, it may be preferred to apply a mask prior to applying the fluid to further define the electrode area.
- FIGS. 2A-2D depict examples where electrodes are shared between different functional pairs, in particular, where two electrodes from the pair of electro-stimulation electrodes are shared with a pair of impedance monitoring electrodes.
- the pair of impedance monitoring electrodes can be used for electro-stimulating the excitable cells when not measuring impedance.
- the electrode arrays provide electrode structures for cell electro-stimulation, cell-impedance measurement and extra-cellular recording, as designed on a non-conductive substrate associated with a single well. Turning in more detail to FIG.
- an exemplary electrode array 10A includes an extracellular recording electrode pair formed from two round-circular extra-cellular recording electrodes 12A positioned at about the middle of the entire array 10A and a unitary one-piece reference electrode 14A positioned at opposing ends of the array 10A.
- a pair of interdigitated electrodes (16A, 18A) formed from a plurality of electrode elements 19A function to electro-stimulate a cell population when switched to a electro-stimulation mode and function to measure cell substrate impedance when switched to an impedance monitoring mode.
- These shared electro-stimulation/impedance monitoring electrodes 16A, 18A are shown in a branched configuration. More specifically, a plurality of electrode elements 19 A of each electrode structure 16 A, 18 A are shown having a circle on line configuration.
- each of the two the recording electrodes 12 A is 100 ⁇ ; the distance between two recording electrodes 12A is 2.98 mm; the diameter of circles in the circle-on-line electrode elements 19A is 90 ⁇ , the center-to-center distance between two adjacent circle-on-line electrode elements 19 A is 110 ⁇ ; and the gap between two shared impedance/electro-stimulation electrodes 16A, 18A and covering the recording electrodes 12A is ⁇ 290 ⁇ ⁇ ⁇ .
- Each of the electrodes 12A, 14A, 16A, 18A are connected to a connection pad 26A via an electrical trace 26A
- each electrode array 10B includes two round-circular extracellular recording electrodes 12B and a single unitary one-piece reference electrode 14B. Electrode structures 16B, 18B are used for both electro-stimulation and cell impedance monitoring albeit at different time points by electronic switching.
- each recording electrode 12B is 60 um; the distance between two recording electrodes 12B is 2 mm; the diameter of circles in the circle-on-line electrode elements 19B is 90 um, the center-to-center distance between two adjacent circle-on-line electrode elements 19B is l lOum; the gap between two impedance-electrode-structures 16B, 18B and covering the recording electrodes 12B is ⁇ 290 um.
- each electrode array IOC is configured on a non-conductive substrate associated with a single well.
- the electrode array IOC includes a round-circular extra-cellular recording electrode 12C and a unitary one-piece reference electrode 14C.
- Electrode structures 16C, 18C perform both impedance measurement and electro-stimulation of cells at different time points by electronic switching.
- a plurality of circle-on-circular-line electrode elements 19C form interdigitated electrode structures 16C, 18C.
- the diameter of the recording electrodes 12C is 80 um; the distance between two recording electrodes 12C is 1.44 mm; the diameter of circles in the circle-on-line electrode elements 19C is 90 um, the center-to-center distance between two adjacent circle-on-line electrode elements 19C is HOum.
- FIG. 2D Still another configuration is shown in FIG. 2D, where an electrode array 10D includes two round-circular extra-cellular recording electrodes 12D and a single unitary one-piece reference electrode 14D. Electrode structures 16D, 18D are used for cell impedance monitoring. Electrode Structures 20D, 22D are used for electro-stimulation and for cell impedance monitoring.
- each recording electrode 12D is 60 um; the distance between two recording electrodes 12D is 2 mm; the diameter of circles in the circle-on-line electrode elements 19D is 90 um, the center-to-center distance between two adjacent circle-on-line electrode elements 19D is HOum; the gap between two impedance-electrode-structures 16D, 22D and covering the recording electrodes 12D is ⁇ 290 um.
- configurations including two or more wells, preferably electrodes within each well of the device are individually addressed, meaning that electrical traces and connection pads of the arrays are configured such that an array can be connected to its power source, impedance amplifier or extracellular recording amplifier independent of the operation of an array in a neighboring well and thus each well can operate using different electro-stimulation intervals, perform different measurements and the like without adversely affecting neighboring wells.
- Electrical traces of conductive material used to connect each of the electrodes to a corresponding connection pad can be fabricated of any electrically conductive material.
- the traces can be localized to the surface of the substrate, and can be optionally covered with an insulating layer. Alternatively the traces can be disposed in a second plane of the substrate.
- Electro-stimulation can be accomplished using a variety of different waveforms such as rectangular, ramp, sinusoidal signals and the like. Either uni-polarity or bi-polarity signals can be used, with signal amplitude ranging from -2.5 V to +2.5 V. When pacing cardiomyoctyes electrical signal from between 1V-2V was preferred while electrical signal between about 1.1 -1.3V was most most preferred. In preferred embodiments, the electro-stimulation voltage can be controlled at voltage resolutions up to 2 mV. Maximum frequency of the stimulation signals could be up to 50 kHz.
- each of the pair of electro-stimulation electrodes of an electrode array is connected to a separate connection pad, which is preferably located at the edge of the substrate.
- Connecting the pair of electro-stimulation electrodes to the connection pads can be performed by applying electrical traces of conductive material therebetween. This facilitates connection to a suitable power source by providing an interface at which the power source can connect. Connection to the connection pads is generally performed through the use of electrically conductive pins, clips or the like.
- One or more electro-stimulation electrodes can be shared with either the extracellular recording electrode pair or the pair of impedance monitoring electrodes by timing the switching between the power source that delivers the electro-stimulation signal through the electro-stimulation electrodes and the extracellular recording amplifier or the impedance analyzer.
- extracellular recording is conducted by amplifying and recording electrical voltage signals between a recording electrode(s) and reference electrode(s). Such electrical voltages are induced on the electrodes as a result of ionic current or movement through cell culture media or solution supporting the cells during the experiment as a result of opening and/or closing of different ion channels across cell membrane during the action potential duration.
- the reference electrodes it is desirable and it is recognized for the reference electrodes to have small electrode impedances.
- FIG. 2A shows a schematic representation of such electrode pairs placed on a non-conductive substrate, including a small area recording electrode 12 A and a much larger area reference electrode 14 A.
- the reference electrode 14 is positioned towards the perimeter of the electrode array 10; however, it must not physically contact the recording electrode 12.
- the reference electrode generally, can be a unitary or unbranched electrode and may be of a simple geometry such as a circle, a square and the like. In other embodiments, the reference electrode has a branched configuration, which may result in a large surface for the reference electrode.
- the ratio of the surface area of the reference electrode to that of the recording electrode is more than 2. In other embodiments, the ratio of the surface area of the reference electrode to that of the recording electrode is 10 or more than 10. In still other embodiments, the ratio of the surface area of the reference electrode to that of the recording electrode is 100 or more than 100. In other embodiments the ratio of the surface area of the reference electrode to that of the recording electrode is 1000 or more than 1000. In other the ratio of the surface area of the reference electrode to that of the recording electrode is 10,000 or more than 10,000.
- one or both electrodes of the pair of impedance measurement electrodes is shared with the extracellular recording electrode pair.
- the shared electrode would be used as a reference electrode in the extracellular recording electrode pair. This can be accomplished when the surface area of the impedance monitoring electrode(s) is sufficiently larger than the surface area of the recording electrode to act as a reference electrode.
- the skilled artisan will appreciate that by electrically switching a pair of interdigitated impedance electrodes from impedance monitoring to function as a single reference electrode, the surface area ratio of the combined interdigitated electrodes to recording electrode would substantially increase and thus may be preferable in some instances. Further, it is also possible, though not preferred to utilize an impedance measurement electrode as a recording electrode when the reference electrode is sufficiently larger than the impedance measurement electrode. While not preferred this approach is more likely when using impedance measurement electrode configurations having a small working electrode and large counter electrode as previously detailed in the art.
- each pair includes two or more electrode structures that are constructed to have dimensions and spacing such that they can, when connected to an impedance analyzer, operate as a unit to generate an electrical field in the region of spaces around the impedance electrode structures.
- the electric field is substantially uniform across the pair of impedance electrodes.
- the pair of impedance electrodes includes two impedance measurement electrode structures, each of which includes multiple electrode elements, or substructures, which branch from the electrode structure.
- the electrode structures in each pair have substantially the same surface area.
- Each of the two complementary impedance monitoring electrode structures of a pair connect to a separate connection pad that is preferably located at the edge of the substrate.
- the array includes two pairs of impedance monitoring electrodes separated by a recording electrode region where one or two recording electrodes are positioned on a same plane of the substrate. In such embodiments it is preferred that each electrode structure be assigned to a separate connecting pad however the pairs could be electrically joined such as by connection at a shared connection pad or through an electronic switch.
- each pair of impedance monitorng electrodes of the device has an approximately uniform electrode resistance distribution across the entire pair of electrodes.
- uniform resistance distribution across the pair is meant that when a measurement voltage is applied across the electrode structures of pair of impedance measurement electrodes, the electrode resistance at any given location of the pair is approximately equal to the electrode resistance at any other location on the pair.
- the electrode resistance at a first location on the pair and the electrode resistance at a second location on the pair does not differ by more than 30%. More preferably, the electrode resistance at a first location on the pair and the electrode resistance at a second location on the same pair does not differ by more than 15%. Even more preferably, the electrode resistance at a first location on the pair and a second location on the same pair does not differ by more than 5%. More preferably yet, the electrode resistance at a first location on the pair and a second location on the same pair does not differ by more than 2%.
- Preferred arrangements for electrode elements that form the pair of impedance monitoring electrodes and gaps between the electrodes and electrode buses in a given pair are used to allow all cells, no matter where they land and attach to the pair of impedance measurement electrodes to contribute similarly to the total impedance change measured for the pair.
- the field strength is related to the potential difference between the nearest point on a first electrode structure of the pair and the nearest point on a second electrode structure of the pair. It is therefore desirable to have similar electric potential drops across the electrode elements and across the electrode buses of a given pair.
- the electrode resistance at a location of interest is equal to the sum of the electrode resistance between the nearest point on a first electrode structure (that is the point on the first electrode structure nearest the location of interest) and a first connection pad connected to the first electrode structure and the electrode resistance between the nearest point on a second electrode structure (that is the point on the first electrode structure nearest the location of interest) and a second connection pad connected to the second electrode structure.
- Achieving an approximately uniform distribution across the pair of impedance measurement electrodes can be achieved, for example, by having electrode structures and electrode buses of particular spacing and dimensions (lengths, widths, thicknesses and geometrical shapes) such that the resistance at any single location on the pair is approximately equal to the resistance at any single other location on the pair.
- the electrode elements (or electrode structures) of a given pair will have even spacing and be of similar thicknesses and widths
- the electrode buses of a given pair will be of similar thicknesses and widths
- the electrode traces leading from a given pair to a connection pad will be of closely similar thicknesses and widths.
- a pair of electrode structures is designed such that the lengths and geometrical shapes of electrode elements or structures, the lengths and geometrical shapes of electrode traces, and the lengths and geometrical shapes of buses allow for approximately uniform electrode resistance distribution across the pair.
- electrode structures comprise multiple electrode elements, and each electrode element connects directly to an electrode bus. Electrode elements of a first electrode structure connect to a first electrode bus, and electrode elements of a second electrode structure connect to a second electrode bus. In these embodiments, each of the two electrode buses connects to a separate connection pad via an electrical trace. Although the resistances of the traces contribute to the resistance at a location on the pair, for any two locations on the pair the trace connections from the first bus to a first connection pad and from the second bus to a second connection pad are identical. Thus, in these preferred embodiments trace resistances do not need to be taken into account in designing the geometry of the pair to provide for uniform resistances across the array.
- impedance measurement electrodes between electrode arrays of different wells can share a connection pad.
- one of the impedance measurement electrode structures of at least one of the electrode arrays of the device is connected to a connection pad that also connects to an impedance measurement electrode structure of at least one other of the electrode arrays of another well device.
- each of the two or more arrays has a first impedance monitoring electrode structure connected to a connection pad that connects with an impedance measurement electrode structure of at least one other electrode array of another well, and each of the two or more arrays has a second impedance monitoring electrode structure that connects to a connection pad that does not connect with any other electrode structures or arrays of the device.
- each of the two or more arrays has a first impedance monitoring electrode structure connected to a connection pad that connects with an impedance measurement electrode structure of at least one other electrode array of another well, and each of the two or more arrays has a second impedance monitoring electrode structure that connects to a connection pad that does not connect with any other electrode structures or arrays of the device.
- there are at least two electrode arrays each of which has a first impedance monitoring electrode structure that is connected to a common connection pad and a second impedance monitoring electrode structure that is connected to an independent connection pad.
- Preferred arrays for devices of the present invention include at least one pair of impedance measurement electrodes, each comprising two electrode structures, such as, in the form of a spiral configuration or an interdigitated configuration.
- the pair of impedance monitoring electrodes are fabricated on the substrate, in which the pair comprises two impedance monitoring electrode structures, each of which comprises multiple circle-on-line electrode elements, in which the electrode elements of one electrode structure alternate with the electrode elements of the opposite electrode structure.
- the pair of impedance monitoring electrodes may be provided in configurations, such as interdigitated, circle-on-line, diamond-on-line, concentric, sinusoidal and castellated.
- a central advantage to systems described herein is that they can incorporate two separate and complete recording systems into one single instrument, namely, an extracellular signal recording system and impedance measurement system. This is accomplished by collecting field potential, which is a local readout such as by an extracellular recording electrode and impedance monitoring, which is an entire well readout by at least one pair of impedance electrodes respectively.
- field potential which is a local readout
- impedance monitoring which is an entire well readout by at least one pair of impedance electrodes respectively.
- the interaction of the results obtained from these separate recording system can be used to support each other.
- cardiomyocytes which is associated with elongated morphology of the cells.
- the systems of the present invention can also record cardiomyocyte action potentials or field potentials, allowing detailed electrophysiological analysis and assessment of cardiomyocytes for relatively short duration at a time.
- electro-stimulating cardiomyocytes allow for electrophysiological measurement and impedance measurement of otherwise non-beating cardiomyocytes. The synchronization of electrostimulation with extra-cellular potential recording and cell impedance measurement would allow better and precise control of initiation timing points for excitation process and allow more reproducible measurement of extra-cellular potential and cell impedances.
- impedance readout can be used to monitor the morphological or differentiative behavior of cardiomyocytes in vitro. Certain treatments can induce changes in morphological behavior of cardiomyocytes, such as inducing hypertrophy which is associated with cardiomyocyte elongation and expansion. Because impedance monitoring can detect changes in cell morphology, it can be used to for detection of hypertrophy in cardiomyocytes.
- impedance monitoring reflects the cell growth, which can be correlated through an impedance-based curve, namely, a cell index curve and contraction / relaxation function by impedance beating signals; while extracellular recording reflects cardiac excitation and conduction by field potential signals. Further, this the invention provides the ability to to monitor viability of cardiomyocytes, the field potential of cardiomyocytes, or the excitation-contraction coupling or beating and morphological and differentiative aspects of cardiomyocytes in a label-free manner and real-time manner.
- the devices and systems can also be used to study a neuronal culture preparation, in which impedance monitoring reflects the cell growth, which can be correlated through a cell index growth curve.
- impedance monitoring reflects the cell growth, which can be correlated through a cell index growth curve.
- an impedance electrode can also serve for stimulation in the neuronal cell preparation, while evoking a response for network stimulation by either chemical or electrical could be recorded at the extracellular recording electrode(s).
- the configurations could also be used for any excitable cell cultures and tissue slices, so the system possesses high capacity for multiple applications.
- an exemplary system for electro-stimulation, impedance monitoring and extracellular recording of excitable cells requires electrical connection of a device to a suitable a suitable electro-stimulation power source, impedance analyzer, and/or extracellular recording amplifier.
- the invention provides a system for monitoring excitable cells, which includes a device having at least one well, each well having a bottom having a nonconductive substrate, wherein the substrate has a surface suitable for attachment of excitable cells; a power source configured to deliver an electrical signal capable of electro-stimulating excitable cells; and at least one analyzing module for measuring an electrical property from electro-stimulated excitable cells, characterized in that each well includes a pair of electro-stimulation electrodes configured to receive the electrical signal from the power source thereby delivering an electro-stimulating signal to the well for electro-stimulation of excitable cells attached to the substrate; and at least a second pair of electrodes communicatively coupled to the at least one analyzing module, which is selected from the group consisting
- a the power source 220, impedance analyzer 230 and extracellular recording amplifier 240 are combined into a combmed analyzing module 200, which is operably connected to a multiwall device 100 for electrostimulation and monitoring of excitable cells.
- An electronic switch 210 can selectively switch electrical connection with at least one electrode of the device 100 between the power source 220 and impedance analyzer 230, between the power source 220 and extracellular recording amplifier 240, and/or the impedance analyzer 230 and extracellular recording amplifier 240, thereby providing numerous combinations.
- the combined analyzing module 200 can then be coupled to a computer 300 loaded with software to execute programming or analyze data.
- a system for monitoring excitable cells which includes a device for electro-stimulation and monitoring of excitable cells, a power source capable of delivering an electrical signal to a pair of electro-stimulation electrodes that stimulates excitable cells; at least one analyzing module in the form of an impedance analyzer capable of monitoring cell substrate impedance of cells through the pair of impedance monitoring electrodes or an extracellular recording amplifier capable of recording extracellular potentials of cells through the extracellular recording electrode pair.
- the system is configured to electro- stimulate the excitable cells at a different time compared to measurement from the at least second pair of electrodes.
- Electro-stimulation is accomplished by an electrical signal delivered from the power source to the electro-stimulation electrodes and to attached cells, which can be in the form of a series of electrical pulses. That is, while impedance monitoring and extracellular recording may incorporate different spectra, waveforms or the like that can continue over an extended time, electro-stimulation is typically performed more quickly in a fast on-off approach followed by a delay in the off state to permit measurement of the excitable cells without interference of the electro-stimulation signal. The skilled artisan will appreciate that in some instances the electro-stimulation signal may be at least partially filtered to prevent interference from a lower intensity state. Preferably, electro-stimulation of the excitable cells is performed at a plurality of time intervals.
- the time intervals are at regular time intervals.
- electro-stimulation can be performed by delivering a biphasic pulse of about 0.8-1.5 ms, more preferably about 1 ms and at an output voltage of 1-2 V or more preferably about 1.2 V.
- An extracellular recording amplifier is communicatively coupled to the extracellular recording electrode pair for electrical communication to permit amplifying and recording electrical voltage signals between the recording electrodes and reference electrodes. That is, extracellular recorded voltage signals are recorded as the difference in the electrical potentials between the recording electrode and reference electrode. Such electrical voltages are induced on the electrodes as a result of ionic current or movement through cell culture media or solution supporting the cells during the experiment as a result of opening and/or closing of different ion channels across cell membrane during the action potential duration. In order to achieve improved consistency and reproducibility of the recorded voltage signals, it is desirable to minimize the contribution of any electrical signal from the reference electrode to the recorded voltage signals and to ensure that the majority, if not all, of the recording voltage signals are derived from that on the recording electrode.
- the reference electrodes it is desirable and it is recognized for the reference electrodes to have small electrode impedances.
- the small electrode impedance is achieved by using reference electrodes with large effective surface areas by increasing the ratio of the surface area of the reference electrodes to that of recording electrode by a factor of a hundred, even thousands of times.
- Such small electrode geometry has advantages of recording the electrical potential generated by a small number of the cells located on the recording electrodes. Action potentials from such a small number of the cells tend to be synchronized or nearly synchronized, allowing for a better time resolution for recording extracellular potential and for resolving different features of the recorded potential.
- one limitation of such extracellular recording is that due to small area of such electrodes, there tends to be large variations in recorded signals between different recorded electrodes of the same geometry in the same wells (if multiple recording electrodes are positioned inside a single well) or different wells.
- insufficient number of the cells is added to the well to cover all the recording electrodes, it is possible that some recording electrodes may not show any recorded signal or only show recorded signals of very small magnitude.
- different recording electrodes may show significantly different extracellular potential waveforms. For this reason, it may be preferable to have at least two recording electrodes positioned at about the middle of the array an in some instances more.
- Extra-cellular potentials from each such recording electrode can amplified and recorded separately.
- the user can then pick and choose appropriate signal waveforms recorded from individual recording electrodes for data analysis.
- a preferred approach is to culture a layer of excitable cells such that the layer covers all recording electrodes.
- the impedance analyzer is communicatively coupled to impedance monitoring electrodes to monitor impedance.
- the impedance analyzer is capable of measuring impedance between 0.1 ohm and 10 5 ohm in frequency range of lHz to 1 MHz.
- the impedance analyzer is preferably capable of measuring both resistance and reactance (capacitive reactance and inductive reactance) components of the impedance.
- the impedance analyzer is capable of measuring impedance between 1 ohm and 10 ohm in frequency range of 1.00 Hz to 300 kHz.
- the impedance analyzer is capable of impedance measurements at millisecond time resolution.
- the required or desired time resolution may vary depending on the excitation cycle of the excitable cell. Excitable cells having shorter excitation cycles or pacing electro-stimulation more quickly, would tend to require faster time resolution.
- 500 millisecond time resolution is sufficient, such that at least two consecutive impedance measurements are between about 300 milliseconds and about 500 milliseconds apart.
- impedance measurement at millisecond time resolution includes at least two consecutive impedance measurements less than 100 milliseconds apart. In some instances the at least two consecutive impedance measurements are less than 50 milliseconds or less than 40 milliseconds apart.
- the at least two consecutive impedance measurements are less than 20 milliseconds apart. In some instances at least two consecutive impedance measurements are less than 10 milliseconds apart. In some instances millisecond time resolution includes two consecutive impedance measurements between 1 millisecond and 5 milliseconds, between 5 milliseconds and 10 milliseconds, between 10 milliseconds and 20 milliseconds, between 20 milliseconds and 40 milliseconds, or between 40 milliseconds and 50 milliseconds apart. In some instances millisecond time resolution includes at least two consecutive impedance measurements between 50 milliseconds and 100 milliseconds apart. In some instances millisecond time resolution includes at least two consecutive impedance measurements between 100 milliseconds and 150 milliseconds or between 150 and 300 milliseconds apart.
- Achieving millisecond time resolution can be achieved by using fast processing electronic chips for analogue-to-digital conversion, for parallel digital signal processing and data calculation with field-programmable gate array (FPGA) and for fast communication between the impedance measurement circuitry and software.
- FPGA field-programmable gate array
- Another example of includes the use of multiple analogue-to-digital (AD) conversion channels so that analog electronic signals from multiple channels can be converted to digital signals simultaneously.
- AD conversion is important, particular for the system having multiple wells, each of which' s measurement time resolution is required to be in the millisecond resolution.
- the software can issue a command for measuring multiple wells' impedances.
- the measurement circuitry would simultaneously or nearly simultaneously perform signal conversion, signal processing and impedance calculation for multiple wells.
- the multiple impedance data for the multiple wells would be sent over the communication lines to the computer sequentially with one well's data at the same time or simultaneously with more than one well's data being sent at a time.
- the system may be performing multiple tasks simultaneously, for example, while one well's impedance data is being measured and calculated, another well's impedance data may be communicated and sent over the communication lines to the computer.
- millisecond time resolution for impedance measurement, it becomes possible to resolve individual beating cycles of cardiomyocytes cultured on electrodes and study the excitation, contraction and release of beating cells. Whilst theoretically one needs at least two data points for each beating cycle, in practice more than 2 data points are needed for each beating cycle. For example, if cells have a beating rate of 60 beats per minute, i.,e, one beat per second. It would be preferred to have a time resolution of at least 200 milliseconds so that each beating cycle consists of 5 data points. More preferably, the measurement time resolution is 100 milliseconds. Still more preferably, the time resolution is 50 millisconds or less.
- Cell-substrate impedance monitoring at millisecond time resolution can be used to efficiently and simultaneously perform multiple assays by using circuitry of the device station to digitally switch from recording from measuring impedance over an array in one well to measuring impedance over an array in another well. Similarly, groups of wells may be monitored simultaneously and switching between occur between designated groups.
- the system under software control is capable of completing an impedance measurement for an individual well at a single frequency within milliseconds, such as less than 100 milliseconds, less than 40 milliseconds, less than 20 milliseconds, less than 10 milliseconds or between 1 millisecond and 40 milliseconds.
- the user may choose the frequency of measurement for millisecond time resolution.
- one or more electrodes in a pair of electrodes can be shared with another pair of electrodes. Sharing of electrodes can accomplished at least in part by switching the communicative coupling for electrical connection between the power source for electro-stimulation and either the impedance analyzer or extracellular recording amplifier. Alternatively, sharing of electrodes can be accomplished at least in part by switching the communicative coupling for electronic connection between the impedance analyzer and the extracellular recording amplifier. In each instance, switching is preferably performed through an electronic programmable switch and is provided together with the power source, impedance analyzer and extracellular recording amplifier in a combined analyzer, which itself can be coupled to a computer for performing measurement instructions or data analysis.
- a combined analyzer or electromechanical apparatus or assembly capable of interfacing multiwell devices can include one or more platforms or one or more slots for positioning one or more multiwell devices, such as in the form of a device station with carriage.
- the one or more platforms or one or more slots can comprise sockets, pins or other devices for electrically connecting the device to the device station such as interaction through connection pads.
- the system can be configured such that multiwell devices can be positioned in a tissue culture incubator during electrostimulation, extracellular recording or impedance monitoring while the computer and optionally combined analyzer are located outside the tissue culture incubator. This can be accomplished through the electrical connection of the device through a device station that itself is inside the incubator and electrically coupled to a combined analyzer that is outside of the incubator. Alternatively, the combined analyzer can be within the incubator and communicate with the computer that is outside of the incubator.
- the device station or electromechanical apparatus or assembly capable of interfacing multiwell devices includes electronic circuitry that connect to the power source, impedance analyzer, and/or extracellular recording amplifier and can incorporate electronic switches that can switch on and off connections to each of the two or more pairs of electrodes within a well of the multiwell devices used in the system.
- the switches of the device station or electromechanical apparatus or assembly capable of interfacing multiwell devices are controlled by a software program, each of which preferably provides millisecond time resolution.
- the systems of the invention are typically controlled through commands sent from a computer operably connected to the power source, impedance analyzer and extracellular recording amplifier.
- the computer is typically loaded with software that provides two functions. A first is data acquisition and a second is data analysis.
- the software uses graphical interfaces for ease of use.
- the data acquisition software is used to define the experiment, setup recording steps, monitor the raw data, adjust settings and to collect raw data files.
- An example of graphical interface for data acquisition is shown in FIGS. 4A-C, where FIG. 4A shows an interface for entering experimental notes such as experiment name, purpose or the like; FIG. 4B shows a well layout where HL-1 atria cells are seeded at different density from 10,000 in column 1 to 40,000 in column 4, and FIG. 4C shows wells specific settings for, electro-stimulation, impedance monitoring and extracellular recording.
- the software can also analyze impedance data and extracellular recording data.
- An exemplary graphical interface for data analysis is provided in FIG. 4D, which shows a file structure "tree" at the left side for file management, single or multiple channels of raw data file displayed in the middle section of the window and the analysis result displayed at the right side of the window.
- the data analysis software also has the ability to do single field potential waveform analysis.
- FIG. 5 An overview of an exemplary experiment and how it interacts with the software can be seen in FIG. 5, where a first step involves cell preparation 400, such as culturing cells, proceeds through raw data collection 500 using electro-stimulation 510 if extracellular recording or impedance monitoring does not result in desired activity, such as poor beating of cardiomyocytes. After raw data collection 500 data analysis 600 is conducted such as correlation of Impedance and ECR data 620. Finally reports 700 are generated providing the results from the impedance and extracellular recording results in desired formats.
- cell preparation 400 such as culturing cells
- electro-stimulation 510 if extracellular recording or impedance monitoring does not result in desired activity, such as poor beating of cardiomyocytes.
- desired activity such as poor beating of cardiomyocytes.
- data analysis 600 is conducted such as correlation of Impedance and ECR data 620.
- reports 700 are generated providing the results from the impedance and extracellular recording results in desired formats.
- the software can calculate an impedance-based parameter, such as cell index (CI) for one or more time points for one or more wells of the multiwell device through suitable programming.
- the software can also calculate a cell change index (CCI) from impedance measurements of one or more wells of the multiwell device.
- the software can preferably generate plots of impedance-based parameters over time, such as but not limited to impedance-based curves selected from impedance measurements, CI, or CCI.
- the software may perform other analysis as well, such as calculate cell number from CI, generate dose-response curves based on impedance data, calculate IC values based on impedance values, and calculate kinetic parameters of the excitation cycle cell based on impedance-based parameters and impedance-based curves.
- the beating cycle of a cardiomyocyte population is determined, which may include initiation and decay of individual beats. Peaks may be derived from the detection of vectors associated with initiation of beating or beating decay. Peaks may be derived with other methods.
- the change in beating cycle of a cardiomyocyte population is determined in response to a stimulus such as administration of a compound to the cells.
- the software of the impedance monitoring system can also store and display analyses of the data, such as calculated impedance values impedance-based parameters and kinetic parameters derived therefrom, Data can be displayed on a screen, as printed data, or both. Data may be stored on a hard drive for exportation into compatible programs for further analysis or data storage
- the invention provides methods of monitoring excitable cells, methods for montoring cardiomyocyte beating, viability, morphology, assessing cardiotoxic affects associated with administering of one or more compounds to a population of cardiomyocyte or cardiomyocyte precursor cells.
- the methods include obtaining a sample of excitable cells, electro-stimulating the excitable cells; and impedance monitoring and/or extracellular recording of the excitable cells.
- impedance monitoring and extracellular recording is performed simultaneously to achieve simultaneous real time measurements.
- the present invention also discloses an approach for monitoring extracellular field potential, which is an electrical potential produce by cells that is outside of the cell.
- extracellular recording also provides insight as the activity of ion channels, which are of central interest when assessing cardiotoxicity of potential therapeutics.
- a method of monitoring excitable cells includes providing a system for electro-stimulation, impedance monitoring and extracellular recording of excitable cells; adding a sample of excitable cells to the device; electro-stimulating the excitable cells; and impedance monitoring and extracellular recording of the excitable cells.
- a method of monitoring excitable cells includes providing a system for electro-stimulation and impedance monitoring of excitable cells; adding a sample of excitable cells to the device; electro-stimulating the excitable cells; and performing impedance measurements of the excitable cells.
- a method of monitoring excitable cells includes providing a system for electro-stimulation and extracellular recording of excitable cells; adding a sample of excitable cells to the device; electro- stimulating the excitable cells; and performing extracellular recording of the excitable cells.
- the cells that may be monitored include any excitable cells, such as primary cardiomyocytes harvested from animal tissue, cultured cardiomyocytes, cardiomyocyte precursor cells, embryonic stem cells, embryonic stem cell derived cardiomyocytes, cardiomyocyte cell lines, enriched cardiomyocyte cells and the like.
- excitable cells such as primary cardiomyocytes harvested from animal tissue, cultured cardiomyocytes, cardiomyocyte precursor cells, embryonic stem cells, embryonic stem cell derived cardiomyocytes, cardiomyocyte cell lines, enriched cardiomyocyte cells and the like.
- neuronal cells may also be used.
- Obtaining or harvesting suitable excitable cells may be performed using a variety of harvesting, collecting, culturing, purifying, enriching or differentiating techniques known in the art to which the invention belongs. While the device can detect changes, such as impedance change and extracelluar potential in a single cell, preferably samples contain a plurality of cells so that the cells will join together for communication with one another, such as through gap junctions. Clear changes in electrocellular recording and impedance measurement have been identified using population of about 10,000-14,000 cells; however, this is not intended to be limiting.
- Cells may be placed into culture then immediately stimulated or measured; however, it has generally been preferable to culture cells such that they attach to the substrate prior to stimulation. More preferably, cells are grown or differentiated on the substrate for a sufficient time in that they join to form a cell layer over the recording electrodes of the extracellular recording electrode pair and over the pair of impedance monitoring electrodes. In some embodiments, electro-stimulation is performed within 1 hour of placing cells in the device; however, the substrate forming the bottom of the well has been shown suitable for long term culturing and thus cells may be cultured as desired, such as for more than 5 days, more than 10 days, more than 15 days, more than 20 days or even more than one month depending on the interests of the experiment and regular cell culture maintenance.
- impedance monitoring may be used to assess how well cells are attached to the substrate, the viability of the cells or to assess the quantity of cells in the sample prior to electro-stimulation, to assess growth curves or the like.
- impedance or extracellular recording may be used to determine whether electro-stimulation is necessary or desired.
- cardiomyocytes derived from embryonic stem cells will begin to beat spontaneously, which can be detected or measured through impedance and extracellular recording.
- cells that being spontaneous beating can be electro-stimulated to establish a more regular beating or a beating at an increased frequency.
- Excitable cells are electro-stimulated through applying a signal via the pair of electro-stimulation electrodes.
- the pair of electro-stimulation electrodes may be a dedicated pair of electrodes, preferably one or more electrodes within the pair of electro-stimulation electrodes may be shared between the pair of impedance measurement electrodes or the extracellular recording electrode pair. Sharing of the electro-stimulation function is permitted in part because of the fast switching between connectivity to the power source for electro-stimulation and the impedance analyzer or between the power source for electro-stimulation and the extracellular recording amplifier. While the particular specifications of a device can vary, stimulation is generally accomplished by applying voltage in a range of about 1 - 2 V for about 1ms, at an interval of every 1-1.5 seconds or so. Particularly encouraging results were obtained when applying 1.1 V for 1 ms every 1.2-1.3s.
- each well When providing two or more wells, each well may be pulsed together such that electro-stimulation occurs simultaneously in more than one well or pulses may be staggered such that two or more wells are pulsed with different at different interval. Electro-stimulation intervals can be selected through a software and computer interface.
- impedance is measured at millisecond time resolution. For example, resolution on the order of 1-10 ms provides high resolution of beating of cardiomyocytes.
- Impedance measurements may themselves be compared; however, in preferred embodiments a cell index is calculated from impedance measurements as an impedance parameter and plotted over time as an impedance-based curve or cell index curve. Accordingly, a cell index curve may be used as an impedance-based curve for comparison, such as by comparing cell index curves over time.
- cell change index is calculated from cell index and plotted as an impedance based curve. Accordingly, cell change index may be used as impedance-based parameter for comparison, such as by comparing cell change index curves over time.
- a same type of curve will be compared. For example, comparison would involve comparing cell index curves to one another, cell change index curves to one another and the like.
- the cell index (CI) obtained for a given well reflects how many cells are attached to the electrode surfaces in this well and how well cells are attached to the electrode surfaces in the well.
- a higher value of "cell index” indicates that, for same type of the cells and cells under similar physiological conditions, more cells are attached to the electrode surfaces.
- Cell Index is a quantitative measure of cell number present in a well.
- a higher value of "cell index” may also indicate that, for same type of the cells and same number of the cells, cells are attached better (for example, cells spread out more, or cell adhesion to the electrode surface is stronger) on the electrode surfaces.
- a normalize cell index is calculated from the cell index and plotted as an impedance based curve.
- a "normalized cell index" at a given time point is calculated by dividing the Cell Index at the time point by the Cell Index at a reference time point. Thus, the Normalized Cell Index is 1 at the reference time point.
- Normalized cell index is cell index normalized against cell index at a particular time point. In most cases in the present applications, normalized cell index is derived as normalized relative to the time point immediately before a compound addition or treatment. Thus, normalized cell index at such time point (immediately before compound addition) is always unit one for all wells.
- One possible benefit for using such normalized cell index is to remove the effect from difference in cell number in different wells. A well having more cells may produce a larger impedance response following compound treatment. Using normalized cell index, it helps to remove such variations caused by different cell numbers.
- a cell change index is calculated from the cell index.
- a "cell change index" at a given time point is calculated by subtracting the cell index at a standard time point from the cell index at the given time point.
- the cell change index is the absolute change in the cell index from an initial time (the standard time point) to the measurement time.
- CCI is the normalized rate of change in cell index. CCI values can be used to quantify the cell status change.
- the cell index determined by a cell-substrate impedance monitoring system described herein is expected to be a proportionate measure of the cell number in the well since the cell morphology and average extent of cell adhesion to the electrode surfaces among the whole cell population do not exhibit significant changes over time.
- cell index is preferably calculated and plotted over time to form an impedance base curve.
- Impedance based curves over time may be aligned or overlay ed with one another according to electro-stimulation time points.
- two or more impedance-based curves may be aligned or overlayed using a point or time of electro-stimulation as a starting basis.
- each member for comparison is a member of a same parameter. That is, impedance measurements can be compared to one another; cell index, which can be calculated from the impedance measurement, can be compared to one another; or cell change index, which can be calculated from cell index, can be compared to one another.
- impedance measurements can be compared to one another; cell index, which can be calculated from the impedance measurement, can be compared to one another; or cell change index, which can be calculated from cell index, can be compared to one another.
- the impedance based parameters are plotted over time to provide an impedance-based curve then compared, whether an impedance measurement curve, a cell index curve, or cell change index curve to identify differences changes in impedance, which may be associated with administration of a compound, expression of an inserted nucleic acid or the like.
- cell index is calculate from impedance measurements and plotted over time to provide an impedance-based curve in the form of a cell index curve.
- Extracellular recording measures the extracellular potential (also referred to as field potential (FP)) and is a close simulation to its counterpart, intracellular action potential (AP), therefore identifying peaks and wave form changes in field potential can be used to predict ion channel activity. Accordingly, the extracellular recording measurements are plotted over time, typically in microvolts, to identify variations in the field potential (FP). Sampling rate for extracellular recording can be about lKHz, 2 KHz, 5KHz and 10 KHz. Extracellular potential is preferably plotted over time to form a field potential curve.
- Periods or electro-stimulation intervals from two or more impedance curves and/or two or more field potential curves may be overlayed to identify trends or differences in impedance and/or field potential.
- the two or more impedance curves can be from different wells, such as from wells having serial dilutions of a compound or may be from a same well at a later time point.
- the addition of compounds suspected of affecting either the field potential (likely due to affecting ion channels) or impedance of the excitable cells may be added to a culture of cells and changes in impedance or field potential can be identified or measured through the comparison of the an impedance-based parameter and field potential before and after compound addition, such as by comparing cell index curves or field potential curves over time. Accordingly, in preferred embodiments comparisons are performed by comparing cell index curves over time to one another and comparing field potential curves over time to one another. In instances where it is not readily apparent by viewing each curve over time, curves between different electro-stimulation periods can be overlayed and compared using curve comparison algorithms. Accordingly, overlaying impedance curves may identify changes in impedance and overlaying field potential curves may identify changes in field potential.
- the methods are useful in assessing the cardiotoxicity of compounds through monitoring impedance of a beating cell population and identifying any changes after compound administration. For instance, a compound suspected of affecting excitation contraction coupling of the excitable cells can be provided to the well. Impedance monitoring can be performed before and after adding the compound and impedance- based parameters (such as cell index) prior to and after adding the compound can be calculated and compared to identify changes in the impedance parameter in response to the compound and thus predict whether the compound is likely to be cardiotoxic.
- the impedance based parameter is compared between at least two different electro-stimulation intervals; however, three or more, four or more, five or more, six or more and the like intervals can be compared.
- impedance and/or extracellular recording is conducted to assess an effect of a compound, such as its potential cardiotoxicity, on cell.
- An exemplary method would be to provide a culture of cells, electro-stimulate the cells, perform impedance monitoring and/or extracellular recording before and after adding the compound and analyzing the results.
- the analysis could include calculating an impedance-based parameter (such as cell index or cell change index) from impedance prior to and after adding the compound and their comparison to identify changes in the impedance parameter.
- the impedance-based parameter may be plotted over time to form an impedance-based curve before and after administration for comparison.
- extracellular potential before and after administration can be compared such as by comparing field potential curves over time to identify differences.
- Such analysis in response to the compound can be used to predict whether the compound is likely to be cardiotoxic, affects beating, affects cardiomycyte morphology or affects ion channels.
- the impedance based parameter is compared between at least two different electro-stimulation intervals; however, three or more, four or more, five or more, six or more and the like intervals can be compared.
- Compounds for testing are not intended to be limiting and may include organic or inorganic molecules, drugs, peptides, proteins, antibodies, siRNA, shR A, miRNA, cDNA, lipids or any combination thereof.
- the compound can be added to two or more wells in different concentrations to evaluate cardioxtoxicity or activity compared to dose or can be added to two or more wells and administered in same well with an antagonist, such as to further verify suspected findings or mechanism of action.
- impedance- based curves can be used to calculate the compound dose-dependent changes in cardiomyocyte morphology, ion channel, modulation, impedance, field potential or the like and generate an EC-50 value for the potency of the compound.
- extracellular recording permits comparisons with cells at various developmental stages to assess development.
- analysis of impedance curves or extracelluar recording curves after compound administration can be clustered and grouped according to similarities thereby being suggestive of a common mechanism of action. Further, once profiles of known compounds are grouped, unknown compounds can then be tested in such a system, and the impedance-based curves and extracellular recording curves compared to the group, then the compound can be assigned to one or more group based on similarities or differences between curves.
- the present invention is directed to method to assess the effect of gene knockout in an embryonic stem (ES) cell upon differentiating into to a cardiomyocyte, the method including providing a device for monitoring impedance operably connected to an impedance analyzer, wherein the device includes at least two wells; adding wildtype ES cells as control to at least a first well and ES cells with a gene knockout in at least a second well; optionally electro-stimulating cells in each well; monitoring impedance of the at least two wells and optionally determining cell indices from impedance values to generate an impedance-based curve for each well; comparing the impedance-based curves between the first and second wells, and if significantly different, concluding that the gene knockout may affect at least one selected from the group consisting of cardiomyocyte viability, cardiomyocyte morphology, cardiomyocyte beating.
- ES embryonic stem
- the invention also provides a method to assess the effect of gene knockout in an embryonic stem (ES) cell upon differentiating into to a cardiomyocyte, the method including: providing a device for monitoring impedance and extracellular recording, that are operably connected to an impedance analyzer and extracellular recording amplifier, wherein the device includes at least two wells; adding wildtype ES cells as control to at least a first well and ES cells with a gene knockout in at least a second well; monitoring impedance and extracellular recording of the at least two wells and optionally determining cell indices from impedance values to generate an impedance-based curve for each well; comparing the impedance-based curves and field potential curves between the first and second wells, and if significantly different, concluding that the gene knockout may affect at least one selected from the group consisting of cardiomyocyte viability, cardiomyocyte morphology, cardiomyocyte beating or affecting an electrophysiological property of the cardiomyoctye.
- ES embryonic stem
- the present invention is directed to method to assess the effect of a transgene in an embryonic stem (ES) cell upon differentiating into to a cardiomyocyte, the method including providing a device for monitoring impedance operably connected to an impedance analyzer, wherein the device includes at least two wells; adding wildtype ES cells as control to at least a first well and ES cells harboring a transgene knockout in at least a second well; optionally electro-stimulating cells in each well; monitoring impedance of the at least two wells and optionally determining cell indices from impedance values to generate an impedance-based curve for each well; comparing the impedance-based curves between the first and second wells, and if significantly different, concluding that the transgene may affect at least one selected from the group consisting of cardiomyocyte viability, cardiomyocyte morphology, cardiomyocyte beating.
- ES embryonic stem
- the invention also provides a method to assess the effect of a transgene in an embryonic stem (ES) cell upon differentiating into to a cardiomyocyte, the method including: providing a device for monitoring impedance and extracellular recording, that are operably connected to an impedance analyzer and extracellular recording amplifier, wherein the device includes at least two wells; adding wildtype ES cells as control to at least a first well and ES cells harboring a transgene in at least a second well; monitoring impedance and extracellular recording of the at least two wells and optionally determining cell indices from impedance values to generate an impedance- based curve for each well; comparing the impedance-based curves and field potential curves between the first and second wells, and if significantly different, concluding that the transgene may affect at least one selected from the group consisting of cardiomyocyte viability, cardiomyocyte morphology, cardiomyocyte beating or affecting an electrophysiological property of the cardiomyoctye.
- EXAMP embryonic stem
- a system was constructed for electro-stimulation of excitable cells, as well as for impedance measurement and extracellular recording of excitable cells having two electrodes for extracellular recording, and shared electrodes in the form of a pair of interdigitated electrode structures having a circle on line configuration that function both as electro-stimulation electrodes an impedance monitoring electrodes.
- the system was designed with the following specifications.
- the hardware system bandwidth was lHz ⁇ 2 Hz (-3dB).
- the suppression ratio of impedance stimulation signal was > 60 dB.
- the noise level was 10 ⁇ (Vp-p).
- the system had excellent shielding and electromagnetic compatibility (EMC).
- electro-stimulation signal available waveforms are rectangular form, a ramp form, and sinusoidal.
- the polarity can be set for uni-polarity or bi-polarity.
- An exemplary amplitude is -2.5V ⁇ +2.5V@ ⁇ 100mA per channel.
- An exemplary output voltage resolution is 2mV.
- An exemplary rise time (10 to 90 %) of voltage: 0.2 ⁇ 8 @ AU 2V.
- An exemplary time lag between stimulation and voltage output is 5 ⁇ 1 @ amplitude > 200mV.
- An exemplary current output is -250 mA ⁇ +250mA@per channel.
- An exemplary resolution is 12 bit.
- An exemplary time resolution is 10 ⁇ 8.
- a maximum frequency (rectangular waveform) is 50 KHz.
- a stimulation format can stimulate all 96 wells in 96 well plate simultaneously or by column (8 wells). Further, in some instances impedance and extracellular recording measurement could be conducted simultaneously with stimulation.
- the sampling rate for impedance measurement over 96 wells was ⁇ 10 ms.
- the sampling rate for extracellular recording signal was 1 KHz, 2 KHz, 5 KHz, and 10 KHz.
- Maximal sampling channels for ECR signal was maximally 8 channels (wells) in parallel, recorded from either one of two electrocellular recording electrodes in a single well. Data acquisition mode permits extracellular recording only, impedance measurement only, and extracellular recording and impedance measurement simultaneously.
- a gain setting offers 1 K, 2 K, 4 K, and 8 K.
- ADC resolution is 14 bit/ ⁇ 5V, total AD conversion rate of 800K SPS. Temperature rise in a well was lower than 0.4C temperature rise compared to incubator temperature. DC offset is fixed at 0.05Hz, ⁇ lmV. Input voltage range is ⁇ 2.5 mV. Electrode input impedance of gold having a diameter 60 ⁇ /100 ⁇ is ⁇ 300 ⁇ / 1 KHz
- FIG. 6A shows results from eight paralleled ECR signals in the HL-1 atria cells at day 7 with 40,000 cells per well, some channels showed spontaneous field potential (FP) firing but no impedance (IMP) signals. As can be seen, the firing is not paced at a regular rate.
- FP spontaneous field potential
- IMP impedance
- CorAT cells mouse embryonic stem cell derived cardiomyocytes
- FP spontaneous field potentional
- IMP impedance
- FIGS. 7B-C show results from 200 ⁇ and 400 ⁇ .
- FIG. 5A is control without Sotalol
- FIG. 5B shows treated wells or test wells with 200 ⁇
- FIG. 5C shows treated wells or test wells with 400 ⁇ .
- sotalol induced a typical EAD and arrthythmias which indicating the primarily target of sotalol is the IKr (hERG) as it was well characterized and published in literature.
- the other ion channels (INa and ICa) were secondarily inhibited; this may due the delay of recovery of membrane potential repolarization, so the available portion of excitable INa and ICa channels were reduced.
- FIG. 8A shows an ECR and IMP overlay with Quinidine added at 0 ⁇ .
- FIG. 8B shows an ECR and IMP overlay with Quinidine added at 2 ⁇ .
- FIG 8C shows an ECR and IMP overlay with Quinidine added at 4 ⁇ .
- FIG. 8D shows an ECR and IMP overlay with Quinidine added at 8 ⁇ .
- FIG. 8E shows an ECR and IMP overlay with Quinidine added at 16 ⁇ .
- FIG. 8F shows an ECR overlay of from FIGS. 8A-E.
- FIG. 8G shows an overlay of impedance-based curves of FIGS. 8A-E.
- Cor.AT cells are mouse embryonic stem cell derived cardiomyocytes that are engineered to express the GFP protein and puromycin protein for selection. These cells are a 100% pure population of cardiomyocytes that beat spontaneously in culture and express all the repertoire of ionic currents typical of a normal cardiomyocytes such as calcium, potassium and sodium.
- the cells were seeded in the wells of Cardio-ECR plates coated with fibronectin at 10 ug/mL and at a density of 9
- the cells were allowed to form a monolayer and the media was changed to fresh media on daily basis. On the 9 th day after seeding the cells were subjected to field stimulation.
- the cardiomyocytes were field stimulated at 1.2 second duration with a biphasic pulse of 1 ms total length and an output voltage of 1.05 V. The total duration of stimulation was for 40 seconds.
- Both the field potential and impedance signals were dynamically monitored by the Cardio-ECR System. As shown in FIG. 9, application of the stimulation pulse caused regular pacing of the Cor.AT cells as measured primarily by the impedance signal (Red Trace) which signifies contraction of the cardiomyocytes. The actual ECR signal during the stimulation phase (Blue Trace) is overwhelmed by the field stimulation signal but can be observed when there is no stimulation.
- Red Trace impedance signal
- Rat neonatal primary cardiomyocytes are spontaneously beating cardiomyocytes that are used as a model system for studying heart function. This model is well- established for the study of the transport and toxicity of drugs and electrophysiological characterization. Neonatal rat cardiomyocytes are prepared and harvested as follows:
- Both the field potential and impedance signals were dynamically monitored by the Cardio-ECR System. As shown in FIG. 10, application of the stimulation pulse caused regular pacing of the rat neonatal primary cells as measured primarily by the impedance signal (Red Trace) which signifies contraction of the cardiomyocytes. The actual ECR signal during the stimulation phase (Blue Trace) is overwhelmed by the field stimulation signal but can be observed when there is no stimulation.
- Red Trace impedance signal
- Electro-stimulation was then applied at electro-stimulation parameters of 1.1 V intensity, lms pulse width, 1.3 s stimulation interval.
- FIG. 11A prior to electrostimulation, the HL-1 cells showed no measureable changes in impedance (IMP) or extracellular recording field potential (FP); however, FIG. 11B shows electro-stimulation induced FP in the extracellular recording measurement and thus a "waking up" of the cells.
- IMP impedance
- FP extracellular recording field potential
- FIG. 11C shows an overlay of the extracellular recording field potentials.
- the slow component of the induced FP was gradually inhibited.
- HL-1 cells were cultured on a device having a pair of electro- stimulation electrodes, a pair of impedance measurement electrodes and a recording and reference electrode pair. Electro-stimulation was then applied at electro-stimulation parameters of 1.1 V intensity, 1ms pulse width, 1.3 s stimulation interval. As shown in FIG. 12 A, prior to electro-stimulation, the HL-1 cells showed no measureable changes in impedance (IMP) or extracellular recording field potential (FP); however, FIG. 12B shows electro-stimulation induced FP in the extracellular recording measurement and thus a "waking up" of the cells followed by lack of FP after stopping electro-stimulation.
- IMP impedance
- FP extracellular recording field potential
- FIG. 12G shows the overlap of the field potential traces from FIGS. 12A-F. Based on the overlapped trace analysis, we can see that the FP was dose dependently inhibited by L type Ca2+ channel blocker, Nifedipine, the inhibition effect was mainly attributed to the blocking the Ca2+ peak (slow component followed by the initial fast Na+ peak).
- CorAT cells were cultured on a device having a pair of electro-stimulation electrodes, a pair of impedance measurement electrodes and a recording and reference electrode pair.
- CorAT cells with a density of 35,000 per well were paced by applying 1.05 V at every 1.2 seconds for a duration of about 40 seconds.
- FIGS. 13A-B pacing was induced to produce reproducible plots of both impedance (shown in cell index) and extracellular field potential; however, when pacing by electrostimulation stopped, both impedance and field potential were irregular.
- impedance and field potential are overlayed whereas in FIG. 13B impedance is the upper display and extracellular recording of field potential the lower.
- FIG. 13C shows a single interval of electro-stimulation showing a relationship between change in impedance (top) and extracellular recording field potential (lower)
- Rat primary cardiomyocytes were harvested and cultured on a device having a pair of electro-stimulation electrodes, a pair of impedance measurement electrodes and a recording and reference electrode pair. At day 5, the cells had a cell density ofl4K per well.
- FIGS. 14A-B showed the regular pacing of the cardimyocytes and the reproducible impedance and field potential responses; however, when pacing stopped the regular impedance and field potential profiles also stopped.
- FIG. 14 A shows impedance as an overlay with field potential while FIG. 14B shows impedance on the top panel and field potential on the lower panel.
- Our cardio ECR device includes a pair of extracellular recording electrodes, the size of which resemble that of popular multichannel electrode recoding. We found that our electrode configurations could be used for recording of changes in field potential (FP) from cultured neuronal network (see example data below).
- FP field potential
- Dissociated neurons from brain or spinal tissue are seeded in the well of our cardio ECR device, and allowed to mature over the course of three weeks into self- organized networks complete with axons, dendrites and hundreds to thousands of synaptic connections.
- the neuronal networks exhibit spontaneous bursting activity after two weeks of incubation, and the spontaneous activity could be monitored by the either one of the two ECR electrodes.
- the neuronal firing data was recorded by either one of the two ECR electrodes in single well.
- Bicuculline a GABAAR inhibitor
- FIG. 15 A a remarkable increased the FP spontaneous firing frequency in cultured rat cortical neurons was measured on day three.
- This result is consistent with a previous publication that bath application of bicuculline caused large increases in spontaneous spike firing frequency (Ma YL, Weston SE, Whalley BJ, Stephens GJ.
- the phytocannabinoid Delta(9)- tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol. 2008 May;154(l):204-15.
- Glutamate was added to the culture rat cortical neurons and the field potential monitored. As shown in FIG. 15B, Glutamate, a nonselective GluR agonist remarkably increased the FP spontaneous firing amplitude and frequency in rat cultured cortical neurons on day ten.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261730427P | 2012-11-27 | 2012-11-27 | |
US61/730,427 | 2012-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014085727A1 true WO2014085727A1 (en) | 2014-06-05 |
Family
ID=50828504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/072439 WO2014085727A1 (en) | 2012-11-27 | 2013-11-28 | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysilogical properties |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014085727A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3012630A1 (en) * | 2014-10-20 | 2016-04-27 | Haute Ecole d'Ingénierie et de Gestion du Canton de Vaud (HEIG-VD) | A multi electrode array (MEA), methods for producing a MEA and a device containing a MEA |
US9612234B2 (en) | 2008-05-05 | 2017-04-04 | Acea Biosciences, Inc. | Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments |
US9709548B2 (en) | 2008-05-05 | 2017-07-18 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
EP3296727A1 (en) * | 2016-09-19 | 2018-03-21 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
US10067121B2 (en) | 2002-07-20 | 2018-09-04 | Acea Biosciences, Inc. | Dynamic monitoring of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) activity and pathways in living cells using real-time microelectronic cell sensing technology |
US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
US10690677B2 (en) | 2002-12-20 | 2020-06-23 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
US11746328B2 (en) | 2017-03-03 | 2023-09-05 | Agilent Technologies, Inc. | Methods and systems for functional maturation of iPSC and ESC derived cardiomyocytes |
US12049615B2 (en) | 2020-03-29 | 2024-07-30 | Agilent Technologies, Inc. | Systems and methods for electronically and optically monitoring biological samples |
US12066428B2 (en) | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029506A1 (en) * | 2008-05-05 | 2010-02-04 | Xiaobo Wang | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution |
US20110039294A1 (en) * | 2003-11-10 | 2011-02-17 | Xiaobo Wang | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
US20110300569A1 (en) * | 2008-05-05 | 2011-12-08 | Acea Biosciences, Inc. | Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (rtca) cardio instruments |
WO2012043820A1 (en) * | 2010-09-30 | 2012-04-05 | 国立大学法人東京医科歯科大学 | Method and device for myocardial cell evaluation and myocardial toxicity inspection |
-
2013
- 2013-11-28 WO PCT/US2013/072439 patent/WO2014085727A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110039294A1 (en) * | 2003-11-10 | 2011-02-17 | Xiaobo Wang | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
US20100029506A1 (en) * | 2008-05-05 | 2010-02-04 | Xiaobo Wang | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution |
US20110300569A1 (en) * | 2008-05-05 | 2011-12-08 | Acea Biosciences, Inc. | Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (rtca) cardio instruments |
WO2012043820A1 (en) * | 2010-09-30 | 2012-04-05 | 国立大学法人東京医科歯科大学 | Method and device for myocardial cell evaluation and myocardial toxicity inspection |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10067121B2 (en) | 2002-07-20 | 2018-09-04 | Acea Biosciences, Inc. | Dynamic monitoring of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) activity and pathways in living cells using real-time microelectronic cell sensing technology |
US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
US11604197B2 (en) | 2002-12-20 | 2023-03-14 | Agilent Technologies, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
US10725023B2 (en) | 2002-12-20 | 2020-07-28 | Acea Biosciences, Inc. | Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer |
US10690677B2 (en) | 2002-12-20 | 2020-06-23 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
US10620188B2 (en) | 2002-12-20 | 2020-04-14 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
US10168318B2 (en) | 2002-12-20 | 2019-01-01 | Acea Biosciences, Inc. | Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways |
US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
US10012636B2 (en) | 2008-05-05 | 2018-07-03 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
US9612234B2 (en) | 2008-05-05 | 2017-04-04 | Acea Biosciences, Inc. | Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments |
US10533985B2 (en) | 2008-05-05 | 2020-01-14 | Acea Biosciences, Inc | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
US11906508B2 (en) | 2008-05-05 | 2024-02-20 | Agilent Technologies, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
US11360072B2 (en) | 2008-05-05 | 2022-06-14 | Agilent Technologies, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
US9709548B2 (en) | 2008-05-05 | 2017-07-18 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
EP3012630A1 (en) * | 2014-10-20 | 2016-04-27 | Haute Ecole d'Ingénierie et de Gestion du Canton de Vaud (HEIG-VD) | A multi electrode array (MEA), methods for producing a MEA and a device containing a MEA |
WO2016062729A1 (en) * | 2014-10-20 | 2016-04-28 | Haute Ecole D'ingenierie Et De Gestion Du Canton De Vaud (Heig-Vd) | A multi electrode array (mea), methods for producing a mea and a device containing a mea |
US12066428B2 (en) | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
US10969376B2 (en) | 2016-09-19 | 2021-04-06 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
JP2019531125A (en) * | 2016-09-19 | 2019-10-31 | ムラタ インテグレイテッド パッシブ ソリューションズ | Electrical stimulation and monitoring device |
EP3296727A1 (en) * | 2016-09-19 | 2018-03-21 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
WO2018050887A1 (en) * | 2016-09-19 | 2018-03-22 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
CN109716117A (en) * | 2016-09-19 | 2019-05-03 | 村田整合被动式解决方案公司 | Electro photoluminescence and monitoring device |
US10488392B2 (en) | 2016-09-19 | 2019-11-26 | Murata Integrated Passive Solutions | Electrical stimulation and monitoring device |
US11746328B2 (en) | 2017-03-03 | 2023-09-05 | Agilent Technologies, Inc. | Methods and systems for functional maturation of iPSC and ESC derived cardiomyocytes |
US12049615B2 (en) | 2020-03-29 | 2024-07-30 | Agilent Technologies, Inc. | Systems and methods for electronically and optically monitoring biological samples |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10539523B2 (en) | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties | |
US11906508B2 (en) | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution | |
WO2014085727A1 (en) | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysilogical properties | |
US20200278339A1 (en) | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function | |
US8206903B2 (en) | Device and method for electroporation-based delivery of molecules into cells and dynamic monitoring of cell responses | |
CA2760941C (en) | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function | |
US7468255B2 (en) | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology | |
US20240076619A1 (en) | METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES | |
US11346797B2 (en) | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties | |
Lee et al. | Repeated and on-demand intracellular recordings of cardiomyocytes derived from human-induced pluripotent stem cells | |
EP1773980A2 (en) | Method for assaying for natural killer, cytotoxic t- lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology | |
EP1815025B1 (en) | Dynamic monitoring of cell responses to the delivery of molecules into the cell | |
Qin et al. | Biohybrid tongue based on hypothalamic neuronal network-on-a-chip for real-time blood glucose sensing and assessment | |
Egert | Network on chips | |
Egert | NETWORKS ON CHIPS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13857721 Country of ref document: EP Kind code of ref document: A1 |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 61/730,427 Country of ref document: US Date of ref document: 20140804 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13857721 Country of ref document: EP Kind code of ref document: A1 |